BP11145 PLGA 65:35, Hydroxyl Terminated, IV: 0.55–0.65 dl/g, Mw: 70–88 kDa

PLGA 65:35, Hydroxyl Terminated, IV: 0.55–0.65 dl/g, Mw: 70–88 kDa Description

This PLGA polymer, with a 65:35 lactide to glycolide ratio and hydroxyl termination, exhibits defined intrinsic viscosity and molecular weight. Its tailored degradation rate is critical for applications such as controlled drug delivery and tissue engineering. The chemical structure supports predictable hydrolytic breakdown in physiological environments, ensuring compatibility and efficacy in various biomedical research and development processes.

PLGA 65:35, Hydroxyl Terminated, IV: 0.55–0.65 dl/g, Mw: 70–88 kDa Applications

1.         Healthcare and Pharmaceutical
- Used as a matrix in biodegradable implants to achieve controlled drug release by utilising its precise degradation kinetics for sustained therapeutic effect.
- Applied as a scaffold in tissue engineering to facilitate gradual cell integration and tissue regeneration by providing a predictable resorption profile.

2.         Industrial and Research
- Employed in laboratory research for developing bioresorbable devices, utilising its consistent degradation characteristics to simulate in vivo conditions accurately.

PLGA 65:35, Hydroxyl Terminated, IV: 0.55–0.65 dl/g, Mw: 70–88 kDa Packing

The material is packaged in moisture-resistant, sealed containers with anti-static protection to minimise contamination and environmental exposure. Packaging includes an inner protective layer and inert film to preserve the polymer's integrity during storage and transit. Recommended storage is in a cool, dry area with controlled humidity. Custom packaging options are available to meet specific handling requirements.

Additional Information

PLGA polymers are widely recognised for their biodegradability and biocompatibility in scientific and industrial applications. The ratio of lactide to glycolide determines degradation rates and mechanical properties, allowing for precise control over material performance. Hydroxyl termination further enhances the polymer's versatility by enabling chemical modifications for targeted applications.

Understanding the degradation behaviour of PLGA is essential for optimising its use in drug delivery systems and tissue engineering scaffolds. As the polymer breaks down into non-toxic by-products, it minimises adverse biological responses while providing effective, timed release of therapeutic agents. This balance of properties makes PLGA a valuable material in contemporary biomedical research and development.

Regulatory Note: This material is intended for industrial and research applications. It is the customer's responsibility to ensure compliance with all relevant safety and regulatory standards in their intended use.